5-formylhonokiol | 1008715-11-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-formylhonokiol
• 英文别名: 2-hydroxy-5-(2-hydroxy-5-prop-2-enylphenyl)-3-prop-2-enylbenzaldehyde
• CAS: 1008715-11-4
• 化学式: C₁₉H₁₈O₃
• 分子量: 294.35
• InChiKey: FNYGVHUZALWIAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-formylhonokiol 在 盐酸羟胺 、 三乙胺 作用下， 以 甲醇 为溶剂， 反应 3.0h， 生成 5,5'-diallyl-2',4-dihydroxy-[1,1'-biphenyl]-3-carbaldehyde oxime
  参考文献：
  名称：

  Semi-synthesis and anti-proliferative activity evaluation of novel analogues of Honokiol

  摘要：

  A series of honokiol analogues were synthesized by modifying the 5- and/or 3'-position(s) of honokiol to assess their anti-tumor effects. Some compounds exerted more potent anti-proliferative activities than those of honokiol on K562 leukemia cells, A549 alveolar basal epithelial cells, SPC-A1 adenocarcinoma cells and A2780 human ovarian carcinoma cells in vitro. Compounds 2b, 3a, and 3c displayed most potent anti-proliferative activities against these tested cell strains and their anti-drug resistance effects were evaluated in vitro on cisplatin-resistant A2780 human ovarian carcinoma cells. The structure-activity relationship was also proposed. (C) 2009 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2009.06.071
• 作为产物：
  描述：

  氯仿 、 和厚朴酚 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 1.0h， 生成 5-formylhonokiol 、 3-甲酰化和厚朴酚 、 3,5'-diformylated honokiol
  参考文献：
  名称：

  [EN] MITO-HONOKIOL COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF
  [FR] COMPOSÉS MITO-HONOKIOL ET LEURS PROCÉDÉS DE SYNTHÈSE ET D'UTILISATION

  摘要：

  本发明提供了mito-honokiol化合物、其药物组合物以及使用mito-honokiol化合物治疗癌症的方法。

  公开号：

  WO2016201188A1

文献信息

• MITO-HONOKIOL COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF
  申请人：The Medical College of Wisconsin, Inc.

  公开号：EP3307254B1

  公开（公告）日：2020-08-05
• Mito-Honokiol Compounds and Methods of Synthesis and Use Thereof
  申请人：The Medical College of Wisconsin, Inc.

  公开号：US20210070787A1

  公开（公告）日：2021-03-11

  The present invention provides mito-honokiol or mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol or mito-magnolol compounds in the treatment of cancer.
• [EN] MITO-HONOKIOL COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF<br/>[FR] COMPOSÉS MITO-HONOKIOL ET LEURS PROCÉDÉS DE SYNTHÈSE ET D'UTILISATION
  申请人：MEDICAL COLLEGE WISCONSIN INC

  公开号：WO2016201188A1

  公开（公告）日：2016-12-15

  The present invention provides mito-honokiol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol compounds in the treatment of cancer.

  本发明提供了mito-honokiol化合物、其药物组合物以及使用mito-honokiol化合物治疗癌症的方法。
• Semi-synthesis and anti-proliferative activity evaluation of novel analogues of Honokiol
  作者：Youfu Luo、Yongbin Xu、Lijuan Chen、Jia Hu、Cheng Peng、DaChun Xie、Jianyou Shi、Wencai Huang、Guobin Xu、Ming Peng、Jing Han、Rui Li、Shengyong Yang、Yuquan Wei

  DOI：10.1016/j.bmcl.2009.06.071

  日期：2009.8

  A series of honokiol analogues were synthesized by modifying the 5- and/or 3'-position(s) of honokiol to assess their anti-tumor effects. Some compounds exerted more potent anti-proliferative activities than those of honokiol on K562 leukemia cells, A549 alveolar basal epithelial cells, SPC-A1 adenocarcinoma cells and A2780 human ovarian carcinoma cells in vitro. Compounds 2b, 3a, and 3c displayed most potent anti-proliferative activities against these tested cell strains and their anti-drug resistance effects were evaluated in vitro on cisplatin-resistant A2780 human ovarian carcinoma cells. The structure-activity relationship was also proposed. (C) 2009 Published by Elsevier Ltd.